Aktis Oncology (NASDAQ:AKTS) Stock Jumps 5.7% - Here's What Happened

Key Points

• Aktis Oncology shares rose 5.7% to $17.31, while trading volume was 54% below its average.
• Analysts have a “Moderate Buy” consensus rating and an average price target of $35.62; ratings include nine Buys, one Strong Buy, and one Sell.
• In its latest reported quarter, the company missed EPS expectations by $0.01, reporting a loss of $0.44 per share, but revenue of $3.38 million exceeded estimates.

Aktis Oncology (NASDAQ:AKTS - Get Free Report) shares were up 5.7% during trading on Tuesday. The company traded as high as $17.31 and last traded at $17.31. 164,301 shares traded hands during mid-day trading, a decline of 54% from the average session volume of 354,639 shares. The stock had previously closed at $16.37.

Analyst Ratings Changes

Several analysts have recently weighed in on AKTS shares. Wedbush restated an "outperform" rating and issued a $35.00 price objective on shares of Aktis Oncology in a report on Friday, October 2nd. Weiss Ratings lowered Aktis Oncology from a "sell (d+)" rating to a "sell (d)" rating in a report on Friday, October 2nd. BMO Capital Markets began coverage on shares of Aktis Oncology in a research report on Tuesday, August 18th. They issued an "outperform" rating and a $37.00 price target on the stock. JPMorgan Chase & Co. upped their price target on shares of Aktis Oncology from $30.00 to $33.00 and gave the company an "overweight" rating in a report on Tuesday, July 14th. Finally, Wall Street Zen lowered shares of Aktis Oncology from a "hold" rating to a "sell" rating in a research report on Saturday, July 25th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $35.62.

Aktis Oncology Trading Up 5.7%

The company has a market cap of $930.41 million and a price-to-earnings ratio of -21.13. The business has a 50-day moving average price of $19.30 and a 200 day moving average price of $20.88.

Aktis Oncology (NASDAQ:AKTS - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The technology company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The business had revenue of $3.38 million during the quarter, compared to analysts' expectations of $2.70 million. On average, analysts anticipate that Aktis Oncology will post -1.84 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Global Retirement Partners LLC grew its stake in Aktis Oncology by 289.1% during the 3rd quarter. Global Retirement Partners LLC now owns 1,537 shares of the technology company's stock valued at $30,000 after acquiring an additional 1,142 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Aktis Oncology by 8.2% in the third quarter. Russell Investments Group Ltd. now owns 8,391 shares of the technology company's stock worth $163,000 after purchasing an additional 637 shares in the last quarter. Silver Grove Financial Group Inc. purchased a new stake in shares of Aktis Oncology in the third quarter worth approximately $28,000. Mirador Capital Partners LP boosted its holdings in shares of Aktis Oncology by 232.9% during the third quarter. Mirador Capital Partners LP now owns 133,558 shares of the technology company's stock worth $2,600,000 after purchasing an additional 93,434 shares during the period. Finally, GK Wealth Management LLC acquired a new stake in shares of Aktis Oncology during the third quarter worth approximately $26,000. Hedge funds and other institutional investors own 28.84% of the company's stock.

About Aktis Oncology

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company's pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.